{"url_path":"/sec/raph/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1415397/0001213900-26-056181-index.html","accession_number":"0001213900-26-056181","cik":"0001415397","ticker":"RAPH","issuer_name":"Raphael Pharmaceutical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1415397/0001213900-26-056181-index.html","primary_entity_key":"0001415397","primary_entity_name":"Raphael Pharmaceutical Inc."},"word_count":548,"has_tables":true,"body_markdown":"** **\n\n**Item 6. Exhibits**\n\n** **\n\n**EXHIBIT INDEX**\n\n \n\n**Exhibit No.**\n \n**Description**\n\n3.1\n \n[Restated Certificate of Incorporation (incorporated by reference from Amendment No. 2 to our registration statement on Form 10, filed on September 23, 2021).](http://www.sec.gov/Archives/edgar/data/1415397/000121390021049453/ea147809ex3-1_raphael.htm)\n\n \n \n \n\n3.2\n \n[Bylaws (incorporated by reference from Amendment No. 2 to our registration statement on Form 10, filed on September 23, 2021).](http://www.sec.gov/Archives/edgar/data/1415397/000121390021046451/ea146623ex3-2_raphael.htm)\n\n \n \n \n\n10.1\n \n[English\nTranslation of the Amendment to the Service Agreement by and between the Company and Dr. Igal Louria Hayon, dated December 27, 2025\n(incorporated by reference to Exhibit 10.10 in our annual report on Form 10-K filed on March 31, 2026).](https://www.sec.gov/Archives/edgar/data/0001415397/000121390026037402/ea028351401ex10-10.htm)\n\n \n \n \n\n10.2\n \n[English\nTranslation of the Amendment to the Service Agreement by and between the Company and Guy Ofir, dated December 27, 2025 (incorporated\nby reference to Exhibit 10.11 in our annual report on Form 10-K filed on March 31, 2026).](https://www.sec.gov/Archives/edgar/data/0001415397/000121390026037402/ea028351401ex10-11.htm)\n\n \n \n \n\n10.3\n \n[English\nTranslation of the Amendment to the Service Agreement by and between the Company and Shlomo Pilo, dated December 27, 2025\n(incorporated by reference to Exhibit 10.12 in our annual report on Form 10-K filed on March 31, 2026).](https://www.sec.gov/Archives/edgar/data/0001415397/000121390026037402/ea028351401ex10-12.htm)\n\n \n \n \n\n10.4\n \n[English Translation of the Amendment to the Service Agreement by and between the Company and Ajay Kumar Dhadha, dated December 27, 2025 (incorporated by reference to Exhibit 10.13 in our annual report on Form 10-K filed on March 31, 2026).](http://www.sec.gov/Archives/edgar/data/1415397/000121390026037402/ea028351401ex10-13.htm)\n\n \n \n \n\n31.1*\n \n[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).](ea029039001ex31-1.htm)\n\n \n \n \n\n31.2*\n \n[Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).](ea029039001ex31-2.htm)\n\n \n \n \n\n32.1**\n \n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.](ea029039001ex32-1.htm)\n\n \n \n \n\n32.2**\n \n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.](ea029039001ex32-2.htm)\n\n \n \n \n\n101.INS\n \nInline XBRL Instance Document\n\n \n \n \n\n101.SCH\n \nInline XBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n \n \n\n101.DEF\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n \n \n\n101.LAB\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n \n \n\n101.PRE\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n \n \n\n104*\n \nCover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)\n\n \n\n*Filed herewith.\n\n \n\n11\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n**RAPHAEL PHARMACEUTICAL INC.**\n\n \n \n\nDate: May 14, 2026\nBy:\n/s/ Shlomo Pilo\n\n \nName:\nShlomo Pilo\n\n \nTitle:\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n \n \n\nDate: May 14, 2026\nBy:\n/s/ Guy Ofir\n\n \nName:\nGuy Ofir\n\n \nTitle:\nChief Financial Officer\n\n(Principal Financial Officer)\n\n \n\n12\n\n \n\nless than 1 thousand.\n\n0001415397\nfalse\nQ1\n--12-31\n\n0001415397\n\n2026-01-01\n2026-03-31\n\n0001415397\n\n2026-05-14\n\n0001415397\n\n2026-03-31\n\n0001415397\n\n2025-12-31\n\n0001415397\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0001415397\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0001415397\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001415397\n\n2024-12-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001415397\n\n2025-03-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001415397\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001415397\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001415397\n\n2020-10-08\n\n0001415397\n\n2020-10-08\n2020-10-08\n\n0001415397\n\nus-gaap:CommonStockMember\n\n2021-05-14\n2021-05-14\n\n0001415397\n\n2021-05-14\n\n0001415397\n\n2021-05-14\n2021-05-14\n\n0001415397\n\nraph:OfficersMember\n\n2026-03-31\n\n0001415397\n\nraph:OfficersMember\n\n2025-12-31\n\n0001415397\n\nraph:InterestShorttermCreditFromARelatedPartyMember\n\n2026-03-31\n\n0001415397\n\nraph:InterestShorttermCreditFromARelatedPartyMember\n\n2025-12-31\n\n0001415397\n\nraph:ConsultingServicesMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nraph:ConsultingServicesMember\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nraph:StockbasedCompensationMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nraph:StockbasedCompensationMember\n\n2025-01-01\n2025-03-31\n\n0001415397\n\nraph:CFOFeeMember\n\n2026-01-01\n2026-03-31\n\n0001415397\n\nraph:CFOFeeMember\n\n2025-01-01\n2025-03-31\n\nxbrli:shares\n\niso4217:USD\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure"}